T he normal blood serine protease, activated protein C (APC), provides multiple beneficial physiological and pharmacological effects, including antithrombotic, cytoprotective, and regenerative actions, [1] [2] [3] [4] [5] and proteolytic detoxification of extracellular histones. 6 Multiple receptors on various cell types have been implicated as required for APC's cytoprotective cell signaling with most reports emphasizing a role for the APC-endothelial protein C receptor (EPCR)-protease activated receptor (PAR)-1 signaling paradigm in which biased signaling by cleavage of PAR1 at Arg46 may be central. 7, 8 Although direct molecular interactions of purified APC have been well documented for EPCR, PAR1, PAR3, and apolipoprotein E receptor 2 (ApoER2), [1] [2] [3] [4] 6, 7, 9, 10 the multiplicity of cell types and biological activities linked to APC's actions leaves many unanswered questions about mechanisms for APC's beneficial cell signaling activities.
One major pharmacological activity of APC-induced signaling involves its ability to reduce vascular leakage induced by edemagenic mediators (eg, thrombin, vascular endothelial growth factor, Pseudomonas aeruginosa-derived toxins) that involve increased endothelial ras-related C3 botulinum toxin substrate 1 (Rac1) activation and decreased RhoA activation in vitro and in vivo. 1, 5, [7] [8] [9] [11] [12] [13] [14] [15] On monocytic-like U937 cells, ApoER2 promotes APC-induced activation of this receptor's adaptor protein, disabled-1 (Dab1), and of Akt signaling, linked to APC anti-inflammatory actions. 10 ApoER2 is central to the reelin pathway that mediates reelin-induced signaling and neuronal pattern development. [16] [17] [18] [19] [20] [21] [22] Reelin binds ApoER2 and triggers phosphorylation of Dab1 involving the Src family kinases, Src, and Fyn. This ligation of ApoER2 causes activation of phosphatidylinositol-3 kinase (PI3K) and phosphorylation of Akt and glycogen synthase kinase 3β (GSK3β) in neurons. Engagement of endothelial ApoER2 by apoE results in suppression of metastatic endothelial recruitment by melanoma cells, implying that ligation of endothelial ApoER2 by one of its ligands, apolipoprotein E, triggers beneficial signaling. 23 Here, we used the human EA.hy926 transformed endothelial cell line to assess APC's ability to initiate reelin-like signaling and cytoprotection via ApoER2. The results show that APC induces phosphorylation of endothelial disabled-1, and that ApoER2 is required for APC-induced phosphorylation and activation of the PI3K-Akt pathway, activation of endothelial Rac1, and vasculoprotection against thrombin-induced vascular leakage and cytotoxicity.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

ApoER2 Mediates Protective Activity of APC Against Apoptosis
Endothelial cells and other cells contain alternatively spliced ApoER2 variants. 10, 21, 24 When the EA.hy926 cells were analyzed for ApoER2 variants by polymerase chain reaction and sequencing (Methods and Figure I in the online-only Data Supplement), we identified 4 isoforms that are schematically indicated in Figure IC in the online-only Data Supplement with deletions of exons (1) 5, (2) 5 and 15, (3) 5, 15, and 18, and (4) 5 and 18. The N-terminal ligand-binding region includes low-density lipoprotein receptor class A (LA) modules, each containing ≈40 residues. Given the absence of exon 5 from all endothelial ApoER2 variants, these data indicate that endothelial ApoER2 generally lacks LA domains 4 to 6 (Figure IC in the online-only Data Supplement).
Studies of human umbilical vein endothelial cells and EA.hy926 cells showed that APC similarly reduced staurosporine-induced apoptosis for each cell line, 25 and we first showed that this endothelial cell cytoprotection required EPCR and PAR1 for its antiapoptotic activity. 26 To determine whether ApoER2 is also required, small interfering RNA (siRNA) was used to knock down each of these 3 receptors in EA.hy926 cells before apoptosis assays. When 2 different proapoptotic stimuli, staurosporine and tumor necrosis factor-α, were used and apoptosis was monitored using Apopercentage dye uptake ( Figure 1A ) or terminal deoxynucleotidyl transferase dUTP nick end-labeling staining ( Figure 1B) , respectively, the results showed that knocking down any 1 of these 3 receptors ablated APC's antiapoptotic activity ( Figure 1A and 1B; P<0.0002). Because soluble ectodomains of EPCR and ApoER2 bind APC, 10 they were studied as inhibitors of APC-initiated antiapoptotic activity in each apoptosis model. When sApoER2 or sEPCR was preincubated with APC before the apoptosis assays, each one caused loss of APC's antiapoptotic activity ( Figure 1C and 1D) . Predictably, the negative controls, sE86A-EPCR and soluble very low-density lipoprotein receptor, which do not bind APC 27, 28 did not cause loss of activity. When cells subjected to tumor necrosis factor-α-induced apoptosis were stained with terminal deoxynucleotidyl transferase dUTP nick end labeling or Hoechst dye or their combination, the cell images show that APC's antiapoptotic activity was inhibited by its prior incubation with sApoER2 but not with soluble very low-density lipoprotein receptor ( Figure 1E ). These data support the hypothesis that each one of EPCR, PAR1, and ApoER2 was required for APC's antiapoptotic activity under the conditions used.
APC Requires ApoER2, PAR1, Src Kinases, and PI3-Kinase to Induce Akt Phosphorylation in Endothelial Cells
To determine requirements for ApoER2 for APC's activation of Akt in endothelial cells, 7 cells were treated with ApoER2 siRNA or control siRNA prior to APC. Studies to quantify mRNA levels showed that ApoER2 mRNA was knocked down by >80% ( Figure ID in the online-only Data Supplement), and Western blots showed similar reduction of ApoER2 antigen whereas EPCR antigen levels remained normal ( Figure ID in the onlineonly Data Supplement). The ability of APC to cause phosphorylation of Ser473 in Akt was significantly inhibited by knocking down ApoER2 (Figure 2A ), indicating that this phosphorylation required ApoER2. The addition of APC to endothelial cells caused phosphorylation of Tyr232 in Dab1 that was sustained >5 to 60 minutes, and this phosphorylation was significantly inhibited by the Src inhibitor PP2 but not by the control compound, PP3. When the requirements for Src family kinases, PAR1, and PI3K for APC-induced Akt phosphorylation were probed using their inhibitors (PP2, SCH79797, and LY294002, or respective control compounds), the results showed that each of these proteins was required for the typical pattern of APC-induced Akt phosphorylation over the Figure 2B ), it did not reduce the level of Akt phosphorylation seen at 90 minutes, although it retarded this reaction >5 to 60 minutes ( Figure 2C ). This suggests that some pathways of APC-initiated signaling which are less efficient without ApoER2-mediated contributions can eventually augment Akt activation. In summary, these results show that ApoER2 is required for APC-initiated signaling in endothelial cells.
ApoER2 Is Required for Endothelial Barrier Stabilization by APC
The vasculoprotective actions of APC for protecting against thrombin-induced vascular leakage on endothelial cells were described for human pulmonary artery endothelial cells using transendothelial electric resistance assays 11 and for EA.hy.926 human endothelial cells based on fluorescent dye leakage assays. 12 In both those studies, a requirement for the S1P receptor, sphingosine 1-phosphate receptor 1, was shown using siRNA, and a requirement for PI3K was also demonstrated. 11 Additional data showed that EPCR and PAR1 were required for APC's vasculoprotective effects. 1 Therefore, here we used both transendothelial electric resistance and dye (fluorescein isothiocyanate-dextran) leakage bioassays to probe the requirement for ApoER2. Endothelial cells were pretreated with either ApoER2 siRNA or control siRNA and then exposed to either thrombin alone or thrombin plus APC. First, without APC addition, data showed that the extensive amount of thrombin-induced endothelial barrier leakage was the same for cells exposed to ApoER2 siRNA or control siRNA ( Figure 3A ). Second, APC treatment completely ablated thrombin-induced leakage in controls, whereas ApoER2 siRNA treatment significantly diminished by >50%, the ability of APC to prevent thrombin-induced endothelial barrier leakage ( Figure 3A ). When transendothelial electric resistance assays were used for defining thrombin-induced barrier disruption, the conclusions were the same as for fluorescein isothiocyanate-dextran leakage studies ( Figure 3B and 3C) . For cells treated with control siRNA, APC reduced by 50% thrombin-induced barrier disruption ( Figure 3B ), whereas APC had no protective effects when ApoER2 was knocked down ( Figure 3C ). Rac1 activation mediates APC's prevention of thrombininduced vascular leakage. 8, 11 When the effects of knocking down ApoER2 on Rac1 activation were studied, ApoER2 was absolutely essential for the observed APC-induced Rac1 activation ( Figure 3D ). Thus, ApoER2 is required for APC's vasculoprotective activity against thrombin-induced endothelial barrier disruption. requires Apolipoprotein E receptor 2 (ApoER2) in addition to endothelial protein C receptor (EPCR) and protease activated receptor (PAR)-1 for its antiapoptotic activity. A, Endothelial cells transfected with control small interfering RNA (siRNA) or siRNA specific for EPCR, PAR1, or ApoER2 were exposed to proapoptotic staurosporine followed by detected of apoptosis by the APO percentage assay. *P<0.0001 (2-tailed t test). B, Endothelial cells transfected with control siRNA or siRNA specific for EPCR, PAR1, or ApoER2 were exposed to tumor necrosis factor (TNF)-α, 
APC and Reelin Share an LA1 Domain Binding Site in ApoER2
Endothelial ApoER2, similar to other low-density lipoprotein receptor family members, binds its ligands via LA domains. 18, 21, 22, 29 A binding site for reelin on ApoER2's LA1 domain was delineated using mutagenesis, protein structural information, and binding studies. 29 We constructed and purified recombinant wild-type and variant sApoER2 species comprising LA domains 1, 2, 3, and 7 plus endothelial growth factor domains A and B with the LA1 domain mutations, K49P/D50S, W64A, or E68G (numbering according to pro-protein sequence). The mutated 49, 50, and 68 residues involved replacement of ApoER2 residues with those of the highly homologous very low-density lipoprotein receptor. Binding studies using these purified sApoER2 preparations showed that data for each sApoER2 construct fit a binding isotherm for a 1:1 stoichiometry ( Figure 4A ). Mutations of K49P and D50S or of W64A decreased the binding affinity by 75% to 92% when compared with control wild-type sApoER2 ( Figure 4A ), whereas the E68G mutation in ApoER2 caused no significant change in binding affinity ( Figure 4A ). Thus, LA1 domain residues 49, 50, and 64 are essential for normal binding of APC to sApoER2.
Discussion
Although neuronal ApoER2 is widely recognized in the neuroscience literature for neuronal and brain cell signaling and biological outcomes, 21, [30] [31] [32] [33] there is a dearth of data for biological roles for endothelial ApoER2. 23, 24, [34] [35] [36] [37] To explore the importance of endothelial ApoER2 for APC's cytoprotective actions, we used EA.hy926 cells as an endothelial cell surrogate 38, 39 to study some of APC's various activities. Extensive data in this report show that ApoER2 is required for APC's cytoprotective and signaling activities in this cell line. In 2 distinct apoptosis assays that used either staurosporine or tumor necrosis factor-α, data here show that ApoER2 was required for APC's antiapoptotic activity in endothelial cells. Activation of the Akt cell survival pathway can provide an important mechanism to reduce apoptosis. APC-induced signaling caused phosphorylation of both Dab1, a known mediator of ApoER2-dependent signaling, and of Akt. The Src inhibitor, PP2, prevented phosphorylation of Dab1 and significantly delayed the phosphorylation of Akt, thereby implicating the known Dab1 signaling partner Src as mediating APC's signaling. APC-induced Akt phosphorylation was blocked by a PI3K inhibitor and a PAR1 antagonist, indicating that this kinase and this receptor were required for Akt activation. These requirements are partially reminiscent of reelin-initiated activation of Akt downstream of Dab1 phosphorylation that involves Src and PI3K in neurons. [17] [18] [19] 21, 22 Moreover, Akt phosphorylation in our studies was significantly inhibited by knocking down ApoER2. These data indicate that ApoER2 contributes to APC-induced cytoprotective signaling under the conditions of this study. An important protective effect of APC for stressed endothelial cells is its ability to stabilize endothelial barrier function that involves Rac1 activation, which is known to require EPCR and PAR1. 7, 8, 11, 12, 40 When transendothelial electric resistance was used to monitor the time course for thrombininduced barrier disruption in the absence or presence of APC, the data showed that knocking down of ApoER2 ablated the ability of APC to prevent endothelial barrier disruption. Thus, ApoER2 is required for APC's vasculoprotective activity against thrombin-induced endothelial barrier disruption. This discovery is consistent with reports that, in neurons, reelin activates Rac1 via disabled-1, Src family kinases, and PI3K. 20 Studies of the binding of purified sApoER2 molecular variants to APC here indicated that LA1 domain residues 49, 50, and 64 are essential for normal binding of APC to sApoER2. A model of this LA1 domain face containing these residues shows that the surface that putatively binds APC ( Figure 4B , black oval) overlaps the domain surface previously identified as binding reelin ( Figure 4B , yellow oval). 29 It remains to be defined how ligation of this LA1 domain surface mechanistically contributes to intracellular signaling mediated by ApoER2.
APC's cell signaling activities generally require EPCR and APC's proteolytic G-protein-coupled receptor target, namely PAR1, as recently reviewed. 5, [41] [42] [43] However, other receptors such as PAR3, sphingosine 1-phosphate receptor 1, Mac-1, epidermal growth factor receptor, and Tie-2 and other receptors may also contribute, directly or indirectly, to APC's beneficial signaling by transactivation or cross talk. Previously, Figure 3 . Apolipoprotein E receptor 2 (ApoER2) is required for activated protein C (APC)-induced protection against thrombin-induced endothelial barrier leakage. The ability of APC to protect endothelial cells against thrombin-induced barrier disruption was monitored by fluorescein isothiocyanate (FITC)-dextran leakage assays and by transendothelial electric resistance (TER) assays. Cells were pretreated with small interfering RNA (siRNA) against ApoER2 or control siRNA (Methods in the online-only Data Supplement). A, For FITCdextran leakage assays, cells were pretreated with APC (90 nmol/L) for 2 h. After aspiration of medium containing APC, thrombin (IIa; 10 nmol/L) was added for 10 min, and then removed. FITC-dextran was added, after 40 min, media was collected from the outside well, and dye leakage was calculated. A, The binding of recombinant variants of sApoER2 containing LA domains 1, 2, 3, and 7 and epidermal growth factor A and B domains to immobilized APC was determined (Methods in the online-only Data Supplement). Binding data are presented as percentage of wildtype sApoER2 maximum binding that was defined as 100% based on the best fit of the binding data for a simple 1:1 association of wildtype sApoER2 to APC. Bars indicate SEM for data from 3 independent experiments, each with duplicate data points. B, LA1 domain space-filling model based on crystal structure PDB ID 3A7Q 29 is shown with previously identified surface areas for reelin binding indicated by yellow dashed-line oval and newly implicated APC binding surface indicated by black dashed-line oval. This ApoER2 LA1 domain model was prepared using Accelrys DS Viewer Pro software with residues numbered according to Yasui et al. 29 we showed that ApoER2 contributes to APC's actions in U937 cells. 10 Here, we demonstrate that ApoER2 is required for APC's antiapoptotic activity and endothelial barrier stabilization. Moreover, we found that both ApoER2 and PAR1 were necessary for the normal pattern of APC-induced Akt activation in EA.hy926 cells. These requirements are schematically depicted in Figure 5 to indicate the complexity and diversity for receptors that bind APC and directly initiate APC-induced signaling. Localization of EPCR, PAR1, and ApoER2 to caveolae [44] [45] [46] enables localization of the depicted signal initiations that must be integrated for APC's benefits. Specifically, ligation of ApoER2 promotes intracellular interactions between Dab1 that is bound to ApoER2 and Src kinases resulting in phosphorylation of Dab1. In turn, phosphorylated Dab1 may serve as a scaffold that promotes additional protein-protein interactions that ultimately enhance Akt phosphorylation and activation ( Figure 5 ).
In summary, the significance of this article is that ApoER2, which directly binds APC via its LA1 domain, should be considered as a potential mediator of APC's actions on endothelial and possibly other cells not yet studied. Figure 5 . Schematic overview for multiple receptors required for activated protein C (APC)-induced phosphorylation of Akt in endothelial cells, which involves protease activated receptor (PAR) 1 and endothelial protein C receptor in addition to apolipoprotein E receptor 2 (ApoER2). The receptors required for phosphorylation of Akt (p-Akt) can initiate distinct signaling pathways, indicated by dashed lines. These signals are integrated to achieve the optimal level of Akt activation. APC induces the phosphorylation of the adaptor disabled-1 (Dab1) that requires Src family kinases. Dab1 can associate with ApoER2 via the latter's NPxY intracellular sequence, as indicated, and Src can phosphorylate Dab1. Dashed lines are used to indicate that the complete list of specific factors that contribute to these pathways remains unclear.
